ASX 200 Stocks to Buy Right Now
ASX 200 stocks are generally well suited for beginners because of their scale and established market positions but their consistent earnings growth and strategic expansion should be taken into consideration.
The following two ASX 200 stocks are in a good spot right now because of their solid fundamentals and clear growth runways makes them compelling picks for investors who want stability without giving up upside.
Northern Star Resources Limited (ASX: NST)
Northern Star Resources Limited (ASX: NST) would be a solid addition to most portfolios and it reported a strong 1H FY26 result which supports its status as a global gold leader.
The company in 1H FY26 recorded revenue of $3,414 million which is up 19% while underlying EBITDA rose 34% to $1,876 million and pushed the EBITDA margin to 55% as realised gold prices averaged $4,670 per ounce.
Profit growth was even better as underlying NPAT increased 49% to $760 million and underlying EPS reached 53.2 cents per share.
Northern Star stands out as one of the Best ASX 200 stocks to buy right now because of currency debasement, persistent inflation and rising geopolitical tensions.
The KCGM mill expansion is now 86% complete and on schedule which is expected to raise production capacity from FY27 onward.
Sigma Healthcare Limited (ASX: SIG)
Sigma Healthcare Limited (ASX: SIG) released its half year results on 26 February 2026 and reported a strong set of numbers which show the scale benefits of its merged Chemist Warehouse platform and integrated wholesale model.
Sigma is best known as the owner of Chemist Warehouse, Amcal and Discount Drug Stores which together form one of the largest pharmacy networks across Australia.
The company in 1H26 reported normalised revenue of $5.5 billion which rose 14.9% while normalised EBIT reached $582.9 million which increased 18.7% and normalised NPAT came in at $392 million which climbed 19.2%.
Chemist Warehouse branded store sales in Australia increased 17.2% while like for like growth came in at 15% and international store sales rose 24.5% which shows strong customer demand across several regions.
The group now operates 957 domestic and operating cash flow was $317.4 million for the half while net debt to normalised EBITDA improved to 0.6 times which shows a conservative balance sheet and capacity to fund growth.
Management aims to achieve $100 million per year in synergies by FY29 and Sigma is positioning itself as one of the best ASX 200 stocks to buy right now for investors who want scalable earnings growth along with defensive healthcare exposure.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
